CONTACT LENS DRUG DELIVERY DEVICE

• US 20100239637A1
• Filed: 12/11/2009
• Published: 09/23/2010
• Est. Priority Date: 12/11/2008
• Status: Active Grant

• Current Assignee: Children's Medical Center Corporation, Massachusetts Institute of Technology
• Original Assignee: Children's Medical Center Corporation, Massachusetts Eye And Ear Infirmary (Foundation of The Massachusetts Eye and EAR Infirmary Incorporated), Massachusetts Institute of Technology
• Inventors: Hoare, Todd R., Ciolino, Joseph B., Kohane, Daniel S.
• Granted Patent: US 8,414,912 B2
• Time in Patent Office: Days
• US Class Current: 424/429
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: G02C 7/04 Contact lenses for the eyes disinfection or sterilisation of contact lenses A61L12/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner.

Claims

1. A drug-eluting contact lens comprising:

a drug release material comprising at least one drug, wherein the contact lens provides substantially zero-order release of the at least one drug over a period beginning no later than about 120 hours from first exposure of the lens to the eye or physiologically-suitable saline solution.

2. A drug-eluting contact lens as in claim 1, wherein the drug release material comprises a polymer.

3. A drug-eluting contact lens as in claim 1, wherein the drug release material comprises a non-polymeric excipient.

4. A drug-eluting contact lens as in claim 1, wherein the drug release material comprises a multi-layered structure.

7. A drug-eluting contact lens as in claim 1, wherein the contact lens is dimensioned so that, when worn by a subject, the drug release material is positioned over the conjunctiva.

9. A drug-eluting contact lens as in claim 1, further comprising a lens material.

11. A drug-eluting contact lens as in claim 9, wherein the lens material encapsulates the drug release material.

12. A drug-eluting contact lens as in claim 9, wherein the lens material crossing the optical axis is optically transparent.

17. A drug-eluting contact lens as in claim 1, wherein the contact lens contains at least 1 mg of the at least one drug.

19. A drug-eluting contact lens as in claim 1, wherein the contact lens contains at least 100 mg of the at least one drug.

20. A drug-eluting contact lens as in claim 1, wherein the at least one drug comprises a first drug and a second drug, wherein the first drug is released at a different rate than the second drug.

22. A drug-eluting contact lens as in claim 1, wherein the at least one drug comprises an anti-infective agent, an anti-VEGF agent, an anti-inflammatory agent, and/or an intraocular pressure reducing agent.

26. A drug-eluting contact lens as in claim 1, wherein the at least one drug is released over a period of at least 720 hours.

30. A drug-eluting contact lens as in claim 1, wherein the at least one drug is released at a rate of at least 1 microgram per hour.

93. The drug-eluting contact lens of claim 1, wherein the at least one drug is released at a rate of at least 0.001 micrograms per hour.

94. The drug-eluting contact lens of claim 1, wherein the at least one drug is released at a rate of at least 0.01 micrograms per hour.

95. The drug-eluting contact lens of claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 120 hours.

96. A drug-eluting contact lens as in claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 168 hours.

97. A drug-eluting contact lens as in claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 720 hours.

98. A drug-eluting contact lens as in claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 2160 hours.

99. A drug-eluting contact lens as in claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 2880 hours.

100. A drug-eluting contact lens as in claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 4800 hours.

101. A drug-eluting contact lens as in claim 1, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 9600 hours.

5-6. -6. (canceled)

8. (canceled)

10. (canceled)

13-16. -16. (canceled)

18. (canceled)

21. (canceled)

23-25. -25. (canceled)

27-29. -29. (canceled)

31. A drug-eluting contact lens comprising:

an optical pathway wherein the line of vision of a wearer of the contact lens passes through the pathway; and

a substantially continuous drug carrying zone comprising at least one drug for release by the contact lens proximate the eye, the zone surrounding the optical pathway but not residing in the optical pathway, wherein the drug carrying zone is encapsulated by a lens material.

32. A drug-eluting contact lens as in claim 31, wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 120 hours.

33. A drug-eluting contact lens as in claim 31, wherein the at least one drug is released at a rate of at least 0.005 micrograms per hour.

34-37. -37. (canceled)

38. A drug-eluting contact lens comprising:

a drug release material comprising at least one drug, and constructed and arranged to release the drug from the contact lens proximate the eye at a rate of at least 1 microgram per hour, for a period of time of at least 120 hours.

39. A drug-eluting contact lens as in claim 38, wherein the drug release material comprises a polymer.

40. A drug-eluting contact lens as in claim 38, wherein the contact lens provides substantially zero-order release of the at least one drug.

41-92. -92. (canceled)